Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 8Colorectal Neoplasms 6Rectal Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Recurrence 2Osteosarcoma 2Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Cholangiocarcinoma 2Wilms Tumor 1Small Cell Lung Cancer Extensive Stage 1Small Bowel Adenocarcinoma 1Sarcoma 1Rhabdoid Tumor 1Peritoneal Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Metastatic to Liver 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Metastatic Gastric Adenocarcinoma 1Malignant Ascites 1Locally Advanced Rectal Cancer 1Hepatoblastoma 1Gastroesophageal Junction Adenocarcinoma 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1

Interventions

trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1Ramucirumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Gastric Adenocarcinoma × irinotecan sucrosofate × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡